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Summary: Serum amyloid A, an apolipoprotein of high density lipoproteins, is also present to a lesser degree in
low density lipoproteins and is co-localized with apolipoprotein B in atherosclerotic lesions. This study examined
the effect of serum amyloid A on cellular affinity of low density lipoprotein in vitro. 125I-labelled low density
lipoprotein, when loaded with recombinant serum amyloid Al (acute phase isotype) or recombinant serum amyloid
A4 (constitutive isotype), had enhanced binding to both human skin fibroblasts and a murine macrophage cell line,
J774, while its degradation was slightly increased in both cells. The binding of oxidized low density lipoprotein to
J774 cells was also enhanced by addition of recombinant serum amyloid Al or serum amyloid A4, and degradation
of oxidized low density lipoprotein was moderately enhanced by recombinant serum amyloid Al. The effects of
recombinant serum amyloid A on cellular binding of labelled low density lipoprotein were not competed by non-
labelled low density lipoprotein and were diminished in the presence of high density lipoprotein. These findings
suggest that serum amyloid A in low density lipoprotein may promote association of low density lipoprotein
with cells by non-specific adsorption, and high density lipoprotein may prevent such interactions by removal of
serum amyloid A.
Introduction
Serum amyloid A is the putative serum precursor of
amyloid A, the main fibrillar constituent in reactive
amyloid deposits (1, 2). The serum amyloid A protein
family in humans consists of six genetically determined
isotypes (serum amyloid Αία, 1β, 1γ, 2α, 2β, and 4)
(2—5). They are classified into two groups based on the
regulation of their synthesis. One group are the acute
phase isotypes including serum amyloid Al and 2 whose
serum level is markedly increased during inflammation
(2, 6). Acute phase serum amyloid A has been proposed
to be involved in several inflammatory events, such as
leukocyte chemotaxis (7), induction of collagenase (8)
and inhibition of platelet agglutination (9). The other
isotype, constitutive serum amyloid A (serum amyloid
A4), does not behave like acute phase reactants or form
amyloid fibrils (4, 10, 11).
Serum amyloid A proteins are associated primarily with
high density lipoproteins (4, 12), and only a little with
other lipoproteins in circulation (13 — 15). In inflamma-
tory states, high density lipoprotein greatly changes its
composition; increased serum amyloid A, reduced cho-
lesterol, and reduced apolipoprotein A-I (16). Recently,
greater attention has been focussed on the roles of acute
phase serum amyloid A or high density lipoproteins rich
in acute phase serum amyloid A in lipoprotein metab-
olism. Putative biological functions include reduction of
lecithin: cholesterol acyltransferase activity (17), en-
hancement of the affinity of high density lipoprotein to
macrophages (18), involvement in binding cholesterol
(19), reduction of high density lipoprotein-mediated cel-
lular cholesterol efflux (20), and reduction of the anti-
oxidizing effect of high density lipoprotein on low den-
sity lipoprotein (21). Some of these activities may sug-
gest preventative effects of acute phase serum amyloid
A against atherogenesis, whereas others may suggest
promotive effects. No particular function has been pro-
posed for serum amyloid A4.
Both serum amyloid A isotypes have been detected in
human atherosclerotic lesions (22). The distribution of
serum amyloid A in the lesions was identical with that
of apolipoprotein B, the major protein component of low
density lipoproteins. These findings led us to hypothe-
size that serum amyloid A bound to low density lipopro-
tein may affect the uptake of low density lipoprotein by
the cells involved in atherogenesis. In this study,
changes in cellular affinity of low density lipoprotein
when loaded with serum amyloid A in vitro were inves-
tigated.
Materials and Methods
Preparation of lipoproteins and recombinant serum
amyloid A
Low density lipoproteins (d 1.006-1.063 kg/1) and high density
lipoproteins (d 1.063 — 1.21 kg/1) were prepared from plasma of
healthy adults by ultracentrifugation according to the method of
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Hatch and Lee (23). They were dialyzed against 10 mmol/1 phos-
phate buffered saline, pH 7.2. Low density lipoprotein was iodin-
ated (125I) using a lactoperoxidase labelling kit (ICN Biomedicals,
Costa Mesa, CA, USA). Mean specific activity was approximately
2000 counts/min X mg of low density lipoprotein. Recombinant
human serum amyloid Ala and 4 were prepared as previously de-
scribed (11) and solubilized with 50 mmol/1 sodium bicarbonate,
pH 8.O. Protein concentration was determined by the dye-binding
method using a commercial kit (Bio-Rad Laboratories, Hercules,
CA, USA).
Association of serum amyloid A to low density
lipoprotein
Recombinant serum amyloid A (100 g/1) was added to 125I-labelled
low density lipoprotein (100 g/1) to yield final concentrations of
0.1, 1, and 10 μg recombinant serum amyloid A per mg of low
density lipoprotein just before cellular binding or degradation ex-
periments. For control (referred to as 0 μg recombinant serum amy-
loid A per mg of low density lipoprotein), 10 μg of bovine serum
albumin were added per mg of low density lipoproteins. In separate
experiments to determine the amount of added recombinant serum
amyloid A incorporated into low density lipoprotein, the recombi-
nant serum amyloid A and low density lipoprotein mixture were
immediately fractionated by gel filtration chromatography using
consecutive columns of Superose 6 and Superose 12 (Pharmacia
Biotech, Uppsala, Sweden) as previously described (15). The
amount of serum amyloid A in each fraction was measured by an
enzyme-linked immunosorbent assay (10, 24).
Oxidation of low density lipoprotein
125I-labelled low density lipoprotein was incubated with 5 μπιοΐ/ΐ
CuCl2 for 12 hours at room temperature, and immediately used for
the experiments.
Cell cultures
Human skin fibroblasts were obtained from healthy adults and
maintained in fetal calf serum (volume fraction 0.1)-DMEM (Dai-
nippon Pharmaceuticals, Osaka, Japan) at 37 °C in 5% CO2. Cells
between passages 10 and 20 were used in experiments. Murine
macrophage-like cell line J774 was obtained from the American
Type Culture Collection and maintained in the same conditions
as above. For determination of total cellular protein, cells were
extensively washed with fetal calf serum-free DMEM, solubilized
in 2 mol/1 urea, 10 mmol/1 Tris-HCl, 0.5 g/1 Tween 20, pH 8.0, and
subjected to the dye-binding protein assay as above.
Cellular binding and degradation assay
Cellular binding and degradation of I25I-labelled low density lipo-
protein were determined by the method of Goldstein and Brown
(25). Confluent fibroblasts in well dishes (diametre: 5 cm) were
placed in culture medium with lipoprotein-depleted fetal calf serum
(volume fraction 0.1)-DMEM and maintained for 12-15 hours.
For binding studies, the cells were washed with DMEM and then
incubated with 1.5 ml of DMEM containing 10 mg/1 125I-labelled
low density lipoprotein (with or without serum amyloid A loading)
for 2 hours at 4 °C. The cells were washed 3 times with DMEM
and harvested with 100 mmol/1 NaOH. The bound radioactivity
was measured in a gamma counter. For degradation studies, the
cells were incubated with 20 mg/1125I-labelled low density lipopro-
tein in 2 ml of fetal calf serum (volume fraction 0.02)-DMEM for
12 hours at 37 °C in 5% CO2. The culture media were treated with
100 g/1 trichloroacetic acid for 30 min at 4 °C. After centrifugation,
the supernatants containing trichloroacetic acid soluble 125I-la-
belled degradation products were extracted with chloroform as pre-
viously described (25) and counted. Cellular binding and degrada-
tion experiments were also performed with J774 cells the same
way as for fibroblasts. The data were corrected for non-specific
binding or degradation obtained from an assay without cells. Re-
sults were expressed as ng bound or degraded low density lipopro-
tein per mg cellular proteins. All experiments were performed in
triplicate. Data were analyzed using the Student's t-test.
Results
Incorporation of recombinant serum
amyloid A to low density lipoprotein
Gel filtration analysis revealed that the vast majority
of recombinant serum amyloid A after incubation with
low density lipoprotein (1 μ§ of serum amyloid A per
mg of low density lipoprotein) was eluted at the posi-
tion corresponding to low density lipoprotein, a little
at the void volume (possibly self-aggregated forms),
and negligible amounts in lower molecular mass areas
(fig. 1). Serum amyloid Α-loaded low density lipopro-
teins had the same electrophoretic mobility as normal
low density lipoprotein on agarose gel electrophoresis
(fig. 1 inset).
Binding of recombinant serum amyloid A-low
density lipoprotein to fibroblasts
Both serum amyloid A isotypes associated with 125I-
labelled low density lipoprotein increased binding of la-
belled low density lipoprotein to fibroblasts in a dose-
dependent and saturable fashion (fig. 2). Binding of la-
belled low density lipoprotein was not effectively re-
duced under the presence of excess amount of non-la-
belled low density lipoprotein, suggesting that the en-
hanced binding was not receptor-mediated when recom-
binant serum amyloid A was on low density lipoprotein.
In addition, there was no difference in competitive ef-
fects between low density lipoprotein and recombinant
serum amyloid Α-loaded low density lipoprotein when
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Fig. 1 Incorporation of recombinant serum amyloid A into low
density lipoprotein. One thousandth volume of recombinant se-
rum amyloid Al (·) or serum amyloid A4 (o) (2 g/1) was added
to low density lipoprotein (LDL) (2 g/1) yielding a final ratio of
1 ng serum amyloid A per mg of LDL. Fifty μΐ was chromato-
graphed on 2 consecutive columns of Superose 6 (2 X 30 cm)
and Superose 12 (2 X 30 cm) equilibrated and eluted with phos-
phate buffered saline at a flow rate of 0.5 ml/min. Fractions of
0.25 ml were collected and analyzed for acute phase serum
amyloid A or serum amyloid A4 by ELISA. The elution posi-
tions of lipoproteins were determined previously (15). Agarose
gel electrophoresis for LDL and serum amyloid A-incorporated
LDL is shown in the inset.
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Fig. 2 Binding of recombinant serum amyloid Α-loaded low den-
sity lipoprotein to fibroblasts (a: serum amyloid Al, b: serum amy-
loid A4). Cells were incubated with recombinant serum amyloid
Al (*)-loaded or recombinant serum amyloid A4 (A)-loaded 125I-
labelled low density lipoprotein (LDL) (10 mg/1), and bound radio-
activity was determined as described in Materials and Methods.
Experiments were also performed in the presence of 500 μ§ non-
labelled LDL (o; recombinant serum amyloid Al-LDL, Δ; recom-






Fig. 3 Binding of recombinant serum amyloid Α-loaded low den-
sity lipoprotein to fibroblasts in the presence of normal low density
lipoprotein. Cells were incubated with 10 mg/1 125I-labelled low
density lipoprotein (LDL) in the presence of 0, 50, or 500 mg/1
non-labelled LDL (x), recombinant serum amyloid A1-loaded LDL
(·), or recombinant serum amyloid A4-loaded LDL (A) (1 μg re-
combinant serum amyloid A per mg of LDL), and bound radioac-
tivity was determined. Data are shown as means. For clarity, S. E.
is shown only for the result without non-labelled LDL. The magni-
tude of S. E. for the data with non-labelled LDL present was about
the same.
Binding of recombinant serum amyloid A-low
density lipoprotein to J774 cells
Similar to the results from the experiments on fibro-
blasts, both recombinant serum amyloid A isotypes
increased the binding of low density lipoprotein to J774
cells in a dose-dependent and non-specific manner (fig.
4). Oxidized low density lipoprotein had a greater affin-
ity for the cells than non-oxidized low density lipopro-
tein, and both recombinant serum amyloid A enhanced
the cellular bindings of oxidized low density lipoprotein
in a dose-dependent and non-specific manner (fig. 5).
Effect of high density lipoprotein on the
cellular bindings of recombinant serum
amyloid Α-loaded low density lipoprotein
The enhancement of low density lipoprotein binding to
fibroblasts by both recombinant serum amyloid A iso-
types was essentially abolished when high density lipo-
protein isolated from a healthy subject was included in
the incubation mixture of recombinant serum amyloid
Α-loaded 125I-labelled low density lipoprotein and fibro-
blasts (fig. 6). The enhanced binding of both recombi-
nant serum amyloid A isotype-loaded oxidized low den-
sity lipoproteins was also abolished by addition of high
density lipoprotein (data not shown). When the recombi-
nant serum amyloid Α-low density lipoprotein (1 μg of
recombinant serum amyloid A per mg of low density












Fig. 4 Binding of recombinant serum amyloid Α-loaded low den-
sity lipoprotein to J774 cells (a: serum amyloid Al, b: serum amy-
loid A4). Cells were incubated with recombinant serum amyloid
Al (•)-loaded or recombinant serum amyloid A4 (A)-loaded I25I-
labelled low density lipoprotein (LDL) (10 mg/1), and bound radio-
activity was determined as described in Materials and Methods.
Experiments were also performed in the presence of 500 μg non-
labelled LDL (o; recombinant serum amyloid Al-LDL, Δ; recom-
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Fig. 5 Binding of recombinant serum amyloid Α-loaded oxidized
low density lipoprotein to J774 cells (a: serum amyloid Al, b:
serum amyloid A4). Cells were incubated with recombinant serum
amyloid Al (*)-loaded or recombinant serum amyloid A4 (A)-
loaded 12SI-labelled oxidized low density lipoprotein (LDL) (10
mg/1), and bound radioactivity was determined as described in Ma-
terials and Methods. Experiments were also performed in the pres-
ence of 500 μg non-labelled LDL (o; recombinant serum amyloid
Al-LDL, Δ; recombinant serum amyloid A4-LDL). Data are
shown as means ± S. E.
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subjected to gel chromatography, most of the serum
amyloid A eluted in the area corresponding to high den-
sity lipoprotein (fig. 7).
Degradation of recombinant serum amyloid
Α-low density lipoprotein in cells
Recombinant serum amyloid Al- or serum amyloid A4-
loaded low density lipoprotein was degraded more than
normal low density lipoprotein by fibroblasts and J774
cells (tab. 1), but the difference was not statistically sig-
nificant. Compared to the magnitude of increased cellu-








Fig. 6 Effect of high density lipoprotein on binding of low den-
sity lipoprotein and recombinant serum amyloid Α-loaded low den-
sity lipoprotein to fibroblasts. Cells were incubated with 10 mg/l
125I-labelled low density lipoprotein (LDL) (x) or recombinant se-
rum amyloid A1-loaded LDL (·) or recombinant serum amyloid
A4-loaded LDL (A) in the presence of various amounts of normal
high density lipoprotein. The LDL contained 1 μg recombinant se-
rum amyloid Al or recombinant serum amyloid A4 per mg of
LDL. Bound radioactivity was determined as described in Materi-
als and Methods. Data are shown as means. For clarity, S. E. are
shown only for the data without high density lipoprotein. The mag-




Fig. 7 Transfer of recombinant serum amyloid Al from low den-
sity lipoprotein to high density lipoprotein. Fifty μΐ of recombinant
serum amyloid A1-loaded low density lipoprotein (LDL) (2 g
LDL/1, 1 μg recombinant serum amyloid Al per mg of LDL) be-
fore (o) and after (·) mixing with an equal volume of high density
lipoprotein (HDL) (2 g/1 protein) were subjected to gel filtration
on consecutive columns of Superose 6 and Superose 12 as de-
scribed in figure 1. Fractions were analyzed for serum amyloid A
content by ELISA.
sity lipoprotein, the amount of degradation appeared low,
suggesting that recombinant serum amyloid Α-low den-
sity lipoprotein bound to the cell surfaces was not signifi-
cantly internalized. Oxidized low density lipoprotein was
degraded more than native low density lipoprotein by
J774 cells. Recombinant serum amyloid Al significantly
increased oxidized low density lipoprotein degradation
while recombinant serum amyloid A4 had no effect.
Discussion
Apolipoproteins are present on every lipoprotein par-
ticle. Although serum amyloid A is primarily associated
with high density lipoproteins, a lesser association with
other lipoproteins is likely. Indeed, the presence of acute
phase serum amyloid A and constitutive serum amyloid
A (serum amyloid A4) in low density lipoprotein from
inflammatory sera and hypertriglyceridaemic sera,
respectively, has been observed (13, 15). Such condi-
tions may be related to the promotion of the atheroscler-
otic diseases (26, 27) in which low density lipoprotein-
cholesterol is accumulated in plasma and tissues. We
studied the association of serum amyloid A with low
density lipoprotein and its possible implications in disor-
ders of lipoprotein metabolism.
We used human skin fibroblasts and a murine macro-
phage-like cell line, J774, since they have been well-
studied as low density lipoprotein receptor — and scav-
enger receptor — carrying cells, respectively. Recombi-
nant proteins allowed us to examine the effects of two
representative acute phase and constitutive serum amy-
loid A isotypes on the interaction between low density
lipoprotein and cells.
The effect of recombinant serum amyloid Al or serum
amyloid A4 on low density lipoprotein clearly increased
binding of low density lipoprotein to both fibroblasts
and J774 cells. The binding of oxidized low density lipo-
protein to J774 cells was also enhanced by both recom-
binant serum amyloid A isotypes. When several patient
sera were subjected to the same Chromatographie sepa-
ration as in this study followed by serum amyloid A
determinations, both serum amyloid A isotypes in the
peak corresponding to low density lipoprotein were 3%
of those in the high density lipoprotein peak (our unpub-
lished observation). Thus, of the three concentrations of
recombinant serum amyloid A examined, 0.1 and 1 μg
serum amyloid A per mg of low density lipoprotein can
occur in circulation, whereas 10 μg per mg low density
lipoprotein may be rare. However, the possibility that
locally synthesized serum amyloid A (28) may be asso-
ciated at high concentration with low density lipoprotein
cannot be ruled out.
We first speculated that serum amyloid A could alter
low density lipoprotein or scavenger receptor-mediated
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Tab. 1 Effect of recombinant serum amyloid A on cellular degradation of 125I-labelled low density
lipoprotein (LDL).
Tracer LDL degradation : ng/mg cell proteins
Fibroblasts J774 cells
LDL
LDL + recombinant serum amyloid Al
LDL + recombinant serum amyloid A4
Oxidized LDL
Oxidized LDL + recombinant serum amyloid Al













Fibroblasts or J774 cells were incubated with [125I]LDL or oxi-
dized [125I]LDL (20 mg/1) with or without recombinant serum
amyloid A (1 μg per mg of LDL) for 12 hours at 37 °C. The culture
media was used for determination of cellular degradation as de-
scribed in Materials and Methods. Data are shown as means ± S. E.
of triplicate experiments.
* p < 0.05 vs oxidized LDL without recombinant serum amy-
loid A.
nd = not determined.
binding. However, this is unlikely because neither re-
combinant serum amyloid Al or serum amyloid A4 alter
electrostatic charges of low density lipoprotein (fig. 1
inset), neither recombinant serum amyloid Al or serum
amyloid A4 affected receptor-mediated cellular binding
of low density lipoprotein as indicated by competition
experiments (fig. 2), and bound recombinant serum
amyloid Α-loaded low density lipoprotein were not in-
ternalized significantly into cells except for the combi-
nation of recombinant serum amyloid A1-loaded oxi-
dized low density lipoprotein and J774 as indicated by
cellular degradation experiments (tab. 1). Thus, both se-
rum amyloid A isotypes enhance non-specific binding of
low density lipoprotein to cells possibly by hydrophobic
interactions, suggesting that serum amyloid A does not
play an active role in low density lipoprotein metabolism
in vivo. Enhanced degradation of recombinant serum
amyloid A1-loaded oxidized low density lipoprotein by
J774 cells was observed. Increased adsorption of oxi-
dized low density lipoprotein to this macrophage-like
cell, although non-specific, may facilitate the internal-
ization (phagocytosis) of low density lipoprotein. The
absence of a significant effect from recombinant serum
amyloid A4-loaded oxidized low density lipoprotein re-
mains to be clarified.
High density lipoprotein inhibited the effects of serum
amyloid A on low density lipoprotein cellular binding by
removing recombinant serum amyloid A from low den-
sity lipoprotein, due to the greater affinity of serum amy-
loid A for high density lipoprotein than low density lipo-
protein. To date, numerous studies have used purified or
recombinant serum amyloid A to elucidate functions of
this protein. In some of these, high density lipoprotein was
shown to abolish or reduce the experimental effects of se-
rum amyloid A (7). It has been proposed that serum amy-
loid A, dissociated from high sensity lipoprotein, may
produce harmful effects, such as amyloid fibril formation
(11) or promotion of inflammatory reactions (7). Serum
amyloid A on low density lipoprotein may also need to
be scavenged by high density lipoprotein to prevent low
density lipoprotein or damaged low density lipoprotein
from prolonged interactions with cells.
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